About Adjuvant capital
Adjuvant Capital: Investing in Life Sciences for a Healthier World
Adjuvant Capital is a life sciences investment fund that is dedicated to backing ambitious companies that are developing drugs, vaccines, diagnostics, medical devices, and other technologies to address critical global public health challenges. The company was founded in 2019 by Glenn Rockman and Tillman Gerngross with the aim of investing in innovative solutions that can make a real difference in people's lives.
The team at Adjuvant Capital has extensive experience in the life sciences industry and is committed to supporting companies that are working on breakthrough technologies. They believe that by investing in these companies, they can help accelerate the development of new treatments and cures for some of the world's most pressing health problems.
One of the key areas of focus for Adjuvant Capital is infectious diseases. The company recognizes that infectious diseases pose a significant threat to global public health and are responsible for millions of deaths each year. By investing in companies that are developing new vaccines and treatments for infectious diseases such as HIV/AIDS, tuberculosis, malaria, and COVID-19, Adjuvant Capital hopes to make a meaningful impact on global health outcomes.
In addition to infectious diseases, Adjuvant Capital also invests in companies working on treatments for cancer, rare genetic disorders, autoimmune diseases, and other conditions. The company takes a long-term approach to its investments and works closely with its portfolio companies to provide strategic guidance as well as financial support.
Adjuvant Capital has already made several high-profile investments since its founding. In 2020 alone, the company invested $300 million into six different life sciences startups. These included Elevation Oncology (which is developing precision therapies for cancer patients), Immune-Onc Therapeutics (which is working on immunotherapies for cancer), Pandion Therapeutics (which is focused on treating autoimmune disorders), Precision BioSciences (which uses gene editing to develop new treatments), and Vaxcyte (which is developing vaccines for infectious diseases).
Adjuvant Capital's investments are not just about making money – they are also about making a positive impact on the world. The company is committed to investing in companies that have the potential to improve global health outcomes and save lives. By doing so, Adjuvant Capital is helping to create a healthier, more equitable world for everyone.
In conclusion, Adjuvant Capital is a life sciences investment fund that is dedicated to backing innovative companies working on breakthrough technologies in areas such as infectious diseases, cancer, rare genetic disorders, autoimmune diseases, and more. The company takes a long-term approach to its investments and works closely with its portfolio companies to provide strategic guidance as well as financial support. With its focus on improving global health outcomes and saving lives, Adjuvant Capital is making a meaningful impact on the world of life sciences investing.